Regeneron Pharmaceuticals, Inc.
REGNRegeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.
Drugs in Pipeline
106
Phase 3 Programs
60
Upcoming Catalysts
24
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
27 upcoming, 4 past
FDA PDUFA Date multiple myeloma therapy (priority review)
For multiple myeloma. NDA filing. AI-extracted from news: Bristol Myers wins FDA priority review for multiple myeloma therapy
FDA approval for extended dosing interval
Source26 more catalysts beyond 14 days
Start a 7-day free trial to see all upcoming catalysts
Dupixent
Dupilumab
Atopic Dermatitis
Ravulizumab
Paroxysmal Nocturnal Hemoglobinuria
Libtayo
Cemiplimab
Non-Small Cell Lung Cancer
Odronextamab
Diffuse Large B-cell Lymphoma (DLBCL)
aflibercept
Diabetic Macular Edema
Cemdisiran
Paroxysmal Nocturnal Hemoglobinuria
Rilonacept
Gout
cemiplimab
Advanced Cutaneous Squamous Cell Carcinoma
Fasinumab
Osteoarthritis of the Knee or Hip
Fianlimab
Melanoma
Pozelimab
CD55-deficient Protein-losing Enteropathy
Pemetrexed
Non-small Cell Lung Cancer
mibavademab
Generalized Lipodystrophy
Rosuvastatin
Hypercholesterolemia
Rilonacept 80 mg
Intercritical Gout
REGN7508
Venous Thromboembolism (VTE)
Intravitreal Aflibercept Injection 2mg
Neovascular Age-related Macular Degeneration
Sarilumab
COVID-19
Carboplatin
Resectable Non-small Cell Lung Cancer
REGN10933 + REGN10987
Healthy Participants
Gemcitabine
Carcinoma，Non-Small-Cell Lung
Dexamethasone
B-Cell Non-Hodgkin Lymphoma (B-NHL)
Intravitreal aflibercept injection [IAI]
Nonproliferative Diabetic Retinopathy
REGN5713
Allergic Rhinitis
Indomethacin
Acute Gout Flare
aflibercept 8 mg PFS
Diabetic Macular Edema (DME)
Investigator Choice (IC) Chemotherapy
Squamous Cell Carcinoma (SCC)
Suptavumab 30 mg/kg
Respiratory Syncytial Virus Infections
Elotuzumab
Relapsed Refractory Multiple Myeloma (RRMM)
Garetosmab
Fibrodysplasia Ossificans Progressiva
Evinacumab
Hypercholesterolemia
Linvoseltamab
Monoclonal Gammopathy of Undetermined Significance (MGUS)
Atorvastatin
Hypercholesterolemia
Naproxen
Osteoarthritis, Knee
Carfilzomib
Relapsed and/or Refractory Multiple Myeloma (RRMM)
rilonacept 160 mg
Familial Cold Autoinflammatory Syndrome (FCAS)
VEGF Trap-Eye 2.0mg
Macular Edema Secondary to Central Retinal Vein Occlusion
ranibizumab
Macular Degeneration
REGN9933
Venous Thromboembolism
Oral corticosteroids (OCS)
Bullous Pemphigoid
Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)
Diabetic Macular Edema
REGN1908
Allergic Conjunctivitis
Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)
Branch Retinal Vein Occlusion
Aflibercept 8 mg
Neovascular Age-Related Macular Degeneration
aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Macular Degeneration
Apixaban
Atrial Fibrillation (AF)
REGN475
Sciatica
REGN2810
Non-small Cell Lung Cancer
Acetylsalicylic Acid (ASA)
Symptomatic Venous Thromboembolism (VTE)
Pembrolizumab
Melanoma
Alirocumab
Homozygous Familial Hypercholesterolemia
Ezetimibe
Hypercholesterolemia
Cyclophosphamide
Follicular Lymphoma (FL)
Statin
Hypercholesterolemia
REGN5715
Allergic Conjunctivitis
Lenalidomide
Relapsed/Refractory Follicular Lymphoma
Doxorubicin
Follicular Lymphoma (FL)
REGN5714
Allergic Rhinitis
Pozelimab + Cemdisiran
Generalized Myasthenia Gravis
LMT (atorvastatin, simvastatin, or rosuvastatin)
Heterozygous Familial Hypercholesterolemia
Dupilumab
Atopic Dermatitis (AD)
Tocilizumab
Recurrent Ovarian Cancer
AR101
Peanut Allergy
Intravitreal Aflibercept Injection (IAI)
Neovascular Age-Related Macular Degeneration
ALN-ANG3
Diabetic Kidney Disease (DKD)
High-dose aflibercept
Neovascular (Wet) Age-Related Macular Degeneration
REGN5678
Metastatic Castration-resistant Prostate Cancer
FDC fianlimab+cemiplimab
Head and Neck Squamous Cell Carcinoma (HNSCC)
ALN-PNP
Healthy Volunteers
Vonsetamig
Chronic Kidney Disease (CKD)
REGN3918
Paroxysmal Nocturnal Hemoglobinuria (PNH)
ALN-HSD
Metabolic Dysfunction-associated Steatohepatitis (MASH)
ALN-CFB
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Enoxaparin
Venous Thromboembolism
REGN2477
Fibrodysplasia Ossificans Progressiva
REGN5458
Multiple Myeloma
REGN5093
NSCLC
REGN7075
Advanced Solid Tumors
REGN7041
Active Noninfectious Uveitis Affecting the Posterior Segment
REGN1908-1909
Cat Allergy
Trevogrumab-Part A
Obesity
Timothy Grass SCIT
Allergic Rhinitis
REGN5668
Ovarian Cancer
Intravitreal Aflibercept Injection
Diabetic Macular Edema
casirivimab+imdevimab
Healthy
Platinum Doublet
Non-small Cell Lung Cancer
PB
Sepsis-Induced Hypotension
Ubamatamab
Ovarian Cancer
Platinum-based chemotherapy
Non-Small Cell Lung Cancer
REGN5381
Heart Failure
REGN7544
Postural Orthostatic Tachycardia Syndrome (POTS)
VEGF Trap Eye
Macular Degeneration
REGN10933+REGN10987 combination therapy
COVID-19
REGN910-3
Diabetic Macular Edema
REGN5459
Relapsed Multiple Myeloma
REGN7945+Linvoseltamab
Relapsed/Refractory Multiple Myeloma
Low-Dose REGN4461
Generalized Lipodystrophy
BNT116
Advanced Non-Small Cell Lung Cancer
REGV131
Hemophilia B
REGN7999
Non-Transfusion Dependent Beta-Thalassemia (NTDT)
ISA101b
Cervical Cancer
Fixed Dose Combination (FDC) cemiplimab+fianlimab
Melanoma
REGN1033 (SAR391786)
Sarcopenia
REGN1500 250 mg SC/15 mg/kg IV/450 mg SC
Homozygous Familial Hypercholesterolemia
REGN10597
Melanoma
REGN13335
Pulmonary Arterial Hypertension (PAH)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Dupixent Dupilumab | Approved | Atopic Dermatitis | - | - |
Ravulizumab | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria | - | - |
Libtayo Cemiplimab | Phase 3 | Non-Small Cell Lung Cancer | Fast Track | - |
Odronextamab | Phase 3 | Diffuse Large B-cell Lymphoma (DLBCL) | - | - |
aflibercept | Phase 3 | Diabetic Macular Edema | - | - |
Cemdisiran | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria | - | - |
Rilonacept | Phase 3 | Gout | - | - |
cemiplimab | Phase 3 | Advanced Cutaneous Squamous Cell Carcinoma | - | - |
Fasinumab | Phase 3 | Osteoarthritis of the Knee or Hip | - | - |
Fianlimab | Phase 3 | Melanoma | - | - |
Pozelimab | Phase 3 | CD55-deficient Protein-losing Enteropathy | - | - |
Pemetrexed | Phase 3 | Non-small Cell Lung Cancer | - | - |
mibavademab | Phase 3 | Generalized Lipodystrophy | - | - |
Rosuvastatin | Phase 3 | Hypercholesterolemia | - | - |
Rilonacept 80 mg | Phase 3 | Intercritical Gout | - | - |
REGN7508 | Phase 3 | Venous Thromboembolism (VTE) | - | - |
Intravitreal Aflibercept Injection 2mg | Phase 3 | Neovascular Age-related Macular Degeneration | - | - |
Sarilumab | Phase 3 | COVID-19 | - | - |
Carboplatin | Phase 3 | Resectable Non-small Cell Lung Cancer | - | - |
REGN10933 + REGN10987 | Phase 3 | Healthy Participants | - | - |
Gemcitabine | Phase 3 | Carcinoma，Non-Small-Cell Lung | - | - |
Dexamethasone | Phase 3 | B-Cell Non-Hodgkin Lymphoma (B-NHL) | - | - |
Intravitreal aflibercept injection [IAI] | Phase 3 | Nonproliferative Diabetic Retinopathy | - | - |
REGN5713 | Phase 3 | Allergic Rhinitis | - | - |
Indomethacin | Phase 3 | Acute Gout Flare | - | - |
aflibercept 8 mg PFS | Phase 3 | Diabetic Macular Edema (DME) | - | - |
Investigator Choice (IC) Chemotherapy | Phase 3 | Squamous Cell Carcinoma (SCC) | - | - |
Suptavumab 30 mg/kg | Phase 3 | Respiratory Syncytial Virus Infections | - | - |
Elotuzumab | Phase 3 | Relapsed Refractory Multiple Myeloma (RRMM) | - | - |
Garetosmab | Phase 3 | Fibrodysplasia Ossificans Progressiva | - | - |
Evinacumab | Phase 3 | Hypercholesterolemia | - | - |
Linvoseltamab | Phase 3 | Monoclonal Gammopathy of Undetermined Significance (MGUS) | - | - |
Atorvastatin | Phase 3 | Hypercholesterolemia | - | - |
Naproxen | Phase 3 | Osteoarthritis, Knee | - | - |
Carfilzomib | Phase 3 | Relapsed and/or Refractory Multiple Myeloma (RRMM) | - | - |
rilonacept 160 mg | Phase 3 | Familial Cold Autoinflammatory Syndrome (FCAS) | - | - |
VEGF Trap-Eye 2.0mg | Phase 3 | Macular Edema Secondary to Central Retinal Vein Occlusion | - | - |
ranibizumab | Phase 3 | Macular Degeneration | - | - |
REGN9933 | Phase 3 | Venous Thromboembolism | - | - |
Oral corticosteroids (OCS) | Phase 3 | Bullous Pemphigoid | - | - |
Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) | Phase 3 | Diabetic Macular Edema | - | - |
REGN1908 | Phase 3 | Allergic Conjunctivitis | - | - |
Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) | Phase 3 | Branch Retinal Vein Occlusion | - | - |
Aflibercept 8 mg | Phase 3 | Neovascular Age-Related Macular Degeneration | - | - |
aflibercept injection (VEGF Trap-Eye, BAY86-5321) | Phase 3 | Macular Degeneration | - | - |
Apixaban | Phase 3 | Atrial Fibrillation (AF) | - | - |
REGN475 | Phase 3 | Sciatica | - | - |
REGN2810 | Phase 3 | Non-small Cell Lung Cancer | - | - |
Acetylsalicylic Acid (ASA) | Phase 3 | Symptomatic Venous Thromboembolism (VTE) | - | - |
Pembrolizumab | Phase 3 | Melanoma | - | - |
Alirocumab | Phase 3 | Homozygous Familial Hypercholesterolemia | - | - |
Ezetimibe | Phase 3 | Hypercholesterolemia | - | - |
Cyclophosphamide | Phase 3 | Follicular Lymphoma (FL) | - | - |
Statin | Phase 3 | Hypercholesterolemia | - | - |
REGN5715 | Phase 3 | Allergic Conjunctivitis | - | - |
Lenalidomide | Phase 3 | Relapsed/Refractory Follicular Lymphoma | - | - |
Doxorubicin | Phase 3 | Follicular Lymphoma (FL) | - | - |
REGN5714 | Phase 3 | Allergic Rhinitis | - | - |
Pozelimab + Cemdisiran | Phase 3 | Generalized Myasthenia Gravis | - | - |
LMT (atorvastatin, simvastatin, or rosuvastatin) | Phase 3 | Heterozygous Familial Hypercholesterolemia | - | - |
Dupilumab | Phase 3 | Atopic Dermatitis (AD) | - | - |
Tocilizumab | Phase 2 | Recurrent Ovarian Cancer | - | - |
AR101 | Phase 2 | Peanut Allergy | - | - |
Intravitreal Aflibercept Injection (IAI) | Phase 2 | Neovascular Age-Related Macular Degeneration | - | - |
ALN-ANG3 | Phase 2 | Diabetic Kidney Disease (DKD) | - | - |
High-dose aflibercept | Phase 2 | Neovascular (Wet) Age-Related Macular Degeneration | - | - |
REGN5678 | Phase 2 | Metastatic Castration-resistant Prostate Cancer | - | - |
FDC fianlimab+cemiplimab | Phase 2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | - | - |
ALN-PNP | Phase 2 | Healthy Volunteers | - | - |
Vonsetamig | Phase 2 | Chronic Kidney Disease (CKD) | - | - |
REGN3918 | Phase 2 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | - | - |
ALN-HSD | Phase 2 | Metabolic Dysfunction-associated Steatohepatitis (MASH) | - | - |
ALN-CFB | Phase 2 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | - | - |
Enoxaparin | Phase 2 | Venous Thromboembolism | - | - |
REGN2477 | Phase 2 | Fibrodysplasia Ossificans Progressiva | - | - |
REGN5458 | Phase 2 | Multiple Myeloma | OrphanFast TrackBreakthrough | - |
REGN5093 | Phase 2 | NSCLC | - | - |
REGN7075 | Phase 2 | Advanced Solid Tumors | - | - |
REGN7041 | Phase 2 | Active Noninfectious Uveitis Affecting the Posterior Segment | - | - |
REGN1908-1909 | Phase 2 | Cat Allergy | - | - |
Trevogrumab-Part A | Phase 2 | Obesity | - | - |
Timothy Grass SCIT | Phase 2 | Allergic Rhinitis | - | - |
REGN5668 | Phase 2 | Ovarian Cancer | - | - |
Intravitreal Aflibercept Injection | Phase 2 | Diabetic Macular Edema | - | - |
casirivimab+imdevimab | Phase 2 | Healthy | - | - |
Platinum Doublet | Phase 2 | Non-small Cell Lung Cancer | - | - |
PB | Phase 2 | Sepsis-Induced Hypotension | - | - |
Ubamatamab | Phase 2 | Ovarian Cancer | - | - |
Platinum-based chemotherapy | Phase 2 | Non-Small Cell Lung Cancer | - | - |
REGN5381 | Phase 2 | Heart Failure | - | - |
REGN7544 | Phase 2 | Postural Orthostatic Tachycardia Syndrome (POTS) | - | - |
VEGF Trap Eye | Phase 2 | Macular Degeneration | - | - |
REGN10933+REGN10987 combination therapy | Phase 2 | COVID-19 | - | - |
REGN910-3 | Phase 2 | Diabetic Macular Edema | - | - |
REGN5459 | Phase 2 | Relapsed Multiple Myeloma | - | - |
REGN7945+Linvoseltamab | Phase 2 | Relapsed/Refractory Multiple Myeloma | - | - |
Low-Dose REGN4461 | Phase 2 | Generalized Lipodystrophy | - | - |
BNT116 | Phase 2 | Advanced Non-Small Cell Lung Cancer | - | - |
REGV131 | Phase 2 | Hemophilia B | - | - |
REGN7999 | Phase 2 | Non-Transfusion Dependent Beta-Thalassemia (NTDT) | - | - |
ISA101b | Phase 2 | Cervical Cancer | - | - |
Fixed Dose Combination (FDC) cemiplimab+fianlimab | Phase 2 | Melanoma | - | - |
REGN1033 (SAR391786) | Phase 2 | Sarcopenia | - | - |
REGN1500 250 mg SC/15 mg/kg IV/450 mg SC | Phase 2 | Homozygous Familial Hypercholesterolemia | - | - |
REGN10597 | Phase 2 | Melanoma | - | - |
REGN13335 | Phase 2 | Pulmonary Arterial Hypertension (PAH) | - | - |
Atopic Dermatitis
1 drug in this indication
Non-Small Cell Lung Cancer
1 drug in this indication
Multiple Myeloma
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)